# EDGAR Filing Document

**Accession Number:** 0001662774
**File Stem:** 0001193125-25-171664
**Filing Date:** 2025-8
**Character Count:** 2428
**Document Hash:** 040c18a1d608661f08a6218671c34fbb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-171664.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001193125-25-171664

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quince Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001662774
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 901024039
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 273
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-910-5717

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 273
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cortexyme, Inc.
- **DATE OF NAME CHANGE:** 20160104

**Quince Therapeutics, Inc.** 

611 Gateway Boulevard, Suite 273

South San Francisco, CA 94080

August 1, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| RE: | **Quince Therapeutics, Inc.**  |

---

**Registration Statement on Form S-3**

**File No. 333-288971**

Ladies and Gentlemen:

Quince Therapeutics, Inc. (the "***Registrant***") hereby requests that the U.S. Securities and Exchange Commission (the "***Commission***") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on August 5, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Gordon Ho of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Gordon Ho of Cooley LLP, counsel to the Registrant, at (650) 843-5190.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **QUINCE THERAPEUTICS, INC.** | **QUINCE THERAPEUTICS, INC.** |
| By: | /S/ *BRENDAN HANNAH* |
| Name: | Brendan Hannah |
| Title: | Chief Business Officer and Chief Operating Officer |

---

cc: Gordon Ho, Cooley LLP